Herbal and dietary supplement hepatotoxicity

Seminars in Liver Disease

Volumn 29, Issue 4, 2009, Pages 373-382

  Navarro, Victor J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Dietary Supplement Health and Education Act (DSHEA); Hepatotoxicity; Herbal dietary supplements; U.S. Pharmacopeia (USP)

Indexed keywords

2,4 DINITROPHENOL; ALANINE AMINOTRANSFERASE; ANABOLIC AGENT; ANDROSTENEDIONE; ASPARTATE AMINOTRANSFERASE; CHLORPHENIRAMINE; EPHEDRINE; EXOLISE; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYDROXYCUT; KAVA; LIPOKINETIX; METHYLTESTOSTERONE; PHENACETIN; PYRROLIZIDINE ALKALOID; UNCLASSIFIED DRUG; USNIC ACID; VALERIAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AWARENESS; CALLILEPIS; CHAPARRAL; CHELIDONIUM; CHINESE MEDICINE; CIMICIFUGA RACEMOSA; CONSUMER; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; EPHEDRA; FOOD AND DRUG ADMINISTRATION; GERMANDER; GLYCYRRHIZA; HEALTH CARE PERSONNEL; HEPATOMEGALY; HERBAL MEDICINE; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; MEDICAL LITERATURE; MEDICINAL PLANT; MULTIPLE ORGAN FAILURE; NONHUMAN; PATIENT; PELIOSIS HEPATIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; SENNA; UNITED STATES; VEIN OCCLUSION; VISCUM ALBUM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; DRUG APPROVAL; DRUG-INDUCED LIVER INJURY; GOVERNMENT REGULATION; HUMANS; PHARMACOPOEIAS AS TOPIC; PLANT PREPARATIONS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 70449133964     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1240006     Document Type: Article

References (114)

1. Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005 27 (11) 1847-1858
2. FDA Web site. Federal Food, Drug, and Cosmetic Act (FD&C Act). Available at: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/default.htm Accessed May 31, 2009
3. Barnes P M., Powell-Griner E, McFann K, Nahin R L. Complementary and Alternative Medicine Use Among Adults: United States, 2002. Hyattsville, MD National Center for Health Statistics 2004 Advance Data From Vital and Health Statistics, No. 343
4. Ni H, Simile C, Hardy A M. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002 40 (4) 353-358
5. Eisenberg D M., Davis R B., Ettner S L. et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998 280 (18) 1569-1575
6. Brevoort P. The booming US botanical market: a new overview. HerbalGram 1998 44 33-46
7. Ernst E, Pittler M H. Herbal medicine. Med Clin North Am 2002 86 (1) 149-161
8. Thyagarajan S P., Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi M S. Herbal medicines for liver diseases in India. J Gastroenterol Hepatol 2002 17 (Suppl 3) S370-S376
9. National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication No. 984083; Bethesda, MD 1998 Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf Accessed May 31, 2009
10. Blanck H M., Serdula M K., Gillespie C et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 2007 107 (3) 441-447
11. U.S. Food and Drug Administration. Consumer information on dietary supplements. Available at: http://www.fda.gov/Food/DietarySupplements/ ConsumerInformation Accessed May 31, 2009
12. U.S. Food and Drug Administration. Transcripts of FDA press conference on dietary supplements. Available at: http://www.fda.gov/downloads/NewsEvents/ Newsroom/MediaTranscripts/ucm123597.pdf Accessed May 31, 2009
13. U.S. Food and Drug Administration. Guidance, Compliance & Regulatory Information. Available at: http://www.fda.gov/food/DietarySupplements/ GuidanceComplianceRegulatoryInformation Accessed May 31, 2009
14. The United States Pharmacopeia (USP). About USPan overview. Available at: http://www.usp.org/aboutUSP Accessed on May 31, 2009
15. Bhattacharyya L, Cecil T, Dabbah R et al, USP Council of Experts Executive Committee. The value of USP public standards for therapeutic products. Pharm Res 2004 21 (10) 1725-1731
16. De Smet P A. Herbal medicine in Europerelaxing regulatory standards. N Engl J Med 2005 352 (12) 1176-1178
17. Official Journal of the European Union. Directive 2004/24/EC of the European Parliament and of the council amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the community code relating to medicinal products for human use. Available at: http://www.mhra.gov.uk/home/ groups/es-herbal/documents/websiteresources/con009359.pdf Accessed May 31, 2009
18. Ko R J. Adulterants in Asian patent medicines. N Engl J Med 1998 339 (12) 847
19. Huang W F., Wen K C., Hsiao M L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997 37 (4) 344-350
20. Espinoza E O., Mann M-J, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995 333 (12) 803-804
21. Gertner E, Marshall P S., Filandrinos D, Potek A S., Smith T M. Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs. Arthritis Rheum 1995 38 614-617
22. Kang-Yum E, Oransky S H. Chinese patent medicine as a potential source of mercury poisoning. Vet Hum Toxicol 1992 34 (3) 235-238
23. Stickel F, Droz S, Patsenker E, Bgli-Stuber K, Aebi B, Leib S L. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol 2009 50 (1) 111-117
24. Wai C T., Tan B H., Chan C L. et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007 27 465-474
25. Chalasani N, Fontana R J., Bonkovsky H L. et al, Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 (6) 1924-1934, 1934, e1e4
26. Estes J D., Stolpman D, Olyaei A et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003 138 (8) 852-858
27. Garca-Corts M, Borraz Y, Lucena M I. et al. [Liver injury induced by natural remedies: an analysis of cases submitted to the Spanish Liver Toxicity Registry]. Rev Esp Enferm Dig 2008 100 (11) 688-695
28. Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, Bauer R. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 1999 282 (1) 28-29 (Pubitemid 29318925)
29. Yun Y J., Nah S S., Park J H. et al. Assessment of prescribed herbal medicine on liver function in Korea: a prospective observational study. J Altern Complement Med 2008 14 (9) 1131-1136
30. Norris W, Paredes A H., Lewis J H. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008 24 (3) 287-297
31. Lucena M I., Garcia-Cortes M, Cueto R, Lopez-Duran J, Andrade R J. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008 22 141-158
32. Navarro V J., Senior J R. Drug-related hepatotoxicity. N Engl J Med 2006 354 (7) 731-739
33. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002 22 (2) 195-206
34. Seeff L B. Herbal hepatotoxicity. Clin Liver Dis 2007 11 (3) 577-596, vii
35. Schiano T D. Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 2003 7 (2) 453-473
36. U.S. Food and Drug Administration. Warning on Hydroxycut products. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm152152.htm Accessed May 31, 2009
37. Stevens T, Qadri A, Zein N N. Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Ann Intern Med 2005 142 (6) 477-478
38. Dara L, Hewett J, Lim J K. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008 14 (45) 6999-7004
39. Shim M, Saab S. Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci 2009 54 (2) 406-408
40. Jones F J., Andrews A H. Acute liver injury associated with the herbal supplement Hydroxycut in a soldier deployed to Iraq. Am J Gastroenterol 2007 102 (10) 2357-2358
41. Herbalife. Available at: http://herbalife.com Accessed May 31, 2009
42. Elinav E, Pinsker G, Safadi R et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007 47 (4) 514-520
43. Schoepfer A M., Engel A, Fattinger K et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007 47 (4) 521-526
44. Duque J M., Ferreiro J, Salgueiro E, Manso G. [Hepatotoxicity associated with the consumption of herbal slimming products]. Med Clin (Barc) 2007 128 (6) 238-239
45. Chao S, Anders M, Turbay M, Olaiz E, McCormack L, Mastai R. Hepatitis aguda asociada al consumo de Herbalife « a proposito de un caso. Acta Gastroenterol Latinoam 2008 38 274-277
46. US Department of Justice, Drug Enforcement Administration (DEA). Rules 2005-Implementation of the Anabolic Steroid Control Act of 2004. Available at: http://www.deadiversion.usdoj.gov/fed-regs/rules/2005/fr1216.htm Accessed May 31, 2009
47. Brown G A., Vukovich M, King D S. Testosterone prohormone supplements. Med Sci Sports Exerc 2006 38 (8) 1451-1461
48. Shipley A. Steroids detected in dietary tablets. The Washington Post November 30, 2005 EO1
49. Kafrouni M I., Anders R A., Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007 5 (7) 809-812
50. Ishak K G. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981 1 (2) 116-128
51. Erlinger S. Drug-induced cholestasis. J Hepatol 1997 26 (Suppl 1) 1-4
52. National Institute on Drug Abuse (NIDA) InfoFacts. Steroids (anabolic-androgenic). Available at: http://www.nida.nih.gov/Infofacts/steroids. html Accessed May 31, 2009
53. World Health Organization. WHO Pharmaceuticals Newsletter 2003, No. 03. Available at: http://apps.who.int/medicinedocs/en/d/Js4946e/1.4.html Accessed June 4, 2009
54. Gloro R, Hourmand-Ollivier I, Mosquet B et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005 17 (10) 1135-1137
55. Jimenez-Saenz M, Martinez-Sanchez Mdel C. Acute hepatitis associated with the use of green tea infusions. J Hepatol 2006 44 (3) 616-617
56. Mazzanti G, Menniti-Ippolito F, Moro P A. et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009 65 (4) 331-341
57. Molinari M, Watt K DS, Kruszyna T et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006 12 (12) 1892-1895
58. Sarma D N., Barrett M L., Chavez M L. et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008 31 (6) 469-484
59. Javaid A, Bonkovsky H L. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol 2006 45 (2) 334-335, author reply 335336
60. Bonkovsky H L. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006 144 (1) 68-71
61. Isbrucker R A., Edwards J A., Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006 44 (5) 636-650
62. Galati G, Lin A, Sultan A M., O'Brien P J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 2006 40 570-580
63. Takami S, Imai T, Hasumura M, Cho Y M., Onose J, Hirose M. Evaluation of toxicity of green tea catechins with 90-day dietary administration to F344 rats. Food Chem Toxicol 2008 46 (6) 2224-2229
64. Swezey R R., Aldridge D E., LeValley S E., Crowell J A., Hara Y, Green C E. Absorption, tissue distribution and elimination of 4-[(3)h]-epigallocatechin gallate in beagle dogs. Int J Toxicol 2003 22 (3) 187-193
65. Chow H H., Hakim I A., Vining D R. et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005 11 (12) 4627-4633
66. Cohen S M., O'Connor A M., Hart J, Merel N H., Te H S. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004 11 (5) 575-577
67. Lynch C R., Folkers M E., Hutson W R. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006 12 (6) 989-992
68. Levitsky J, Alli T A., Wisecarver J, Sorrell M F. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005 50 (3) 538-539
69. Lontos S, Jones R M., Angus P W., Gow P J. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003 179 (7) 390-391
70. Whiting P W., Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002 177 440-443
71. Mahady G B., Low Dog T, Barrett M L. et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008 15 (4 Pt 1) 628-638
72. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009 16 (1) 72-84
73. Guo L, Shi Q, Fang J L. et al. Review of usnic acid and Usnea barbata toxicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008 26 317-338
74. Han D, Matsumaru K, Rettori D, Kaplowitz N. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 2004 67 (3) 439-451
75. Pramyothin P, Janthasoot W, Pongnimitprasert N, Phrukudom S, Ruangrungsi N. Hepatotoxic effect of (+)usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria. J Ethnopharmacol 2004 90 (2-3) 381-387
76. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007 48 (2) 115-117
77. Miranda E J., McIntyre I M., Parker D R., Gary R D., Logan B K. Two deaths attributed to the use of 2,4-dinitrophenol. J Anal Toxicol 2006 30 (3) 219-222
78. Sanchez W, Maple J T., Burgart L J., Kamath P S. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006 81 (4) 541-544
79. Durazo F A., Lassman C, Han S H. et al. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004 99 (5) 950-952
80. Favreau J T., Ryu M L., Braunstein G et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002 136 (8) 590-595
81. Neff G W., Reddy K R., Durazo F A., Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004 41 (6) 1062-1064
82. Bach N, Thung S N., Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989 87 (1) 97-99
83. Weston C FM, Cooper B T., Davies J D., Levine D F. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987 295 (6591) 183
84. Zuckerman M, Steenkamp V, Stewart M J. Hepatic veno-occlusive disease as a result of a traditional remedy: confirmation of toxic pyrrolizidine alkaloids as the cause, using an in vitro technique. J Clin Pathol 2002 55 (9) 676-679
85. Bras G, Jelliffe D B., Stuart K L. Veno-occlusive disease of the liver with nonportal type of cirrhosis, occurring in Jamaica. Arch Pathol 1954 57 285-300
86. Tandon B N., Tandon H D., Tandon R K., Narndranathan M, Joshi Y K. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976 2 (7980) 271-272
87. Mohabbat O, Younos M S., Merzad A A., Srivastava R N., Sediq G G., Aram G N. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 1976 2 (7980) 269-271
88. Stillman A S., Huxtable R J., Consroe P, Kohnen P, Smith S. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977 73 (2) 349-352
89. Steenkamp V, Stewart M J., Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit 2000 22 (3) 302-306
90. Ridker P M., Ohkuma S, McDermott W V., Trey C, Huxtable R J. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985 88 (4) 1050-1054
91. Stickel F, Egerer G, Seitz H K. Hepatotoxicity of botanicals. Public Health Nutr 2000 3 (2) 113-124
92. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997 26 (Suppl 1) 47-51
93. U.S. Food and Drug Administration. FDA advises dietary supplement manufacturers to remove comfrey products from the market. Available at: http://www.fda.gov/Food/DietarySupplements/Alerts/ucm111219.htm Accessed May 31, 2009
94. Sheikh N M., Philen R M., Love L A. Chaparral-associated hepatotoxicity. Arch Intern Med 1997 157 (8) 913-919
95. Smith B C., Desmond P V. Acute hepatitis induced by ingestion of the herbal medication chaparral. Aust N Z J Med 1993 23 (5) 526
96. Batchelor W B., Heathcote J, Wanless I R. Chaparral-induced hepatic injury. Am J Gastroenterol 1995 90 (5) 831-833
97. Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990 12 (2) 203-206
98. Gordon D W., Rosenthal G, Hart J, Sirota R, Baker A L. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995 273 (6) 489-490
99. Kane J A., Kane S P., Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995 36 (1) 146-147
100. Graham-Brown R. Toxicity of Chinese herbal remedies [letter]. Lancet 1992 340 (8820) 673-674
101. Danan G, Benichou C. Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993 46 (11) 1323-1330
102. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugsII. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993 46 (11) 1331-1336
103. Maria V AJ, Victorino R MM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997 26 (3) 664-669
104. Crdenas A, Restrepo J C., Sierra F, Correa G. Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiflorum. J Clin Gastroenterol 2006 40 (7) 629-632
105. Rochon J, Protiva P, Seeff L B. et al, Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008 48 (4) 1175-1183
106. Jordan M A., Haywood T. Evaluation of Internet websites marketing herbal weight-loss supplements to consumers. J Altern Complement Med 2007 13 (9) 1035-1043
107. Gardiner P, Sarma D N., Low Dog T et al. The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf 2008 17 (10) 962-970
108. Gardiner P, Graham R E., Legedza A T., Eisenberg D M., Phillips R S. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 2006 166 (18) 1968-1974
109. Suchard J R., Suchard M A., Steinfeldt J L. Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 2004 11 (4) 193-197
110. Berman B M., Singh B K., Lao L, Singh B B., Ferentz K S., Hartnoll S M. Physicians' attitudes toward complementary or alternative medicine: a regional survey. J Am Board Fam Pract 1995 8 (5) 361-366
111. U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available at: http://www.fda.gov/medwatch Accessed May 31, 2009
112. U.S. Department of Health and Human Services. Office of Inspector General Report: adverse event reporting for dietary supplements; an inadequate safety valve. Washington, DC; 2001. Available at: http://www.dhhs.gov/oig/oei Accessed June 4, 2009
113. Russmann S, Lauterburg B H., Helbling A. Kava hepatotoxicity. Ann Intern Med 2001 135 (1) 68-69
114. Teschke R, Schwarzenboeck A, Hennermann K H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008 20 (12) 1182-1193